Kennedy Capital Management LLC Buys 6,505 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Kennedy Capital Management LLC increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 26.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 31,426 shares of the medical equipment provider’s stock after purchasing an additional 6,505 shares during the quarter. Kennedy Capital Management LLC’s holdings in Zimmer Biomet were worth $3,320,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Stonebridge Financial Group LLC bought a new stake in shares of Zimmer Biomet in the fourth quarter valued at $25,000. Kentucky Trust Co bought a new stake in Zimmer Biomet in the 4th quarter valued at about $39,000. OFI Invest Asset Management bought a new position in Zimmer Biomet during the fourth quarter worth about $40,000. SRS Capital Advisors Inc. increased its stake in shares of Zimmer Biomet by 146.9% in the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 285 shares in the last quarter. Finally, Atala Financial Inc bought a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $51,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Trading Up 0.0 %

ZBH stock opened at $102.30 on Friday. The company has a market capitalization of $20.36 billion, a PE ratio of 22.99, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $127.32. The company’s 50 day moving average price is $106.31 and its two-hundred day moving average price is $107.04.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the firm posted $2.20 EPS. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.94%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Raymond James dropped their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Barclays lowered their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Finally, Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.